Abbott Laboratories (NYSE:ABT) is one of Goldman Sachs top healthcare stocks. On March 10, Abbott Laboratories (NYSE:ABT) confirmed the launch of its most advanced generation stent, XIENCE Skypoint, in India. The launch is designed to equip doctors in the country with stents that can reach difficult areas and treat a wide range of blockages.

XIENCE Skypoint stents are more flexible and easier to guide through heart arteries, including large vessels. Expected to be of great benefit to doctors treating cardiovascular diseases, the stents are also suited for treating complex heart blockages.

XIENCE Skypoint stands out for its slim, smooth delivery system, which helps doctors guide the stent through the vessel. It also includes a left main indication that helps doctors treat critical segments of the coronary artery.

Abbott is to offer the broadest matrix ever from the XIENCE family to support the treatment of long lesions. It will also help reduce the number of stents required per procedure. The ultimate goal is to offer doctors more options and patients greater confidence to support long-term heart health.

Abbott Laboratories (NYSE:ABT) is a diversified global healthcare company that develops, manufactures, and markets products across four core segments: medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products for all ages.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.